Guidelines for Transitioning from Heparin Infusion to Warfarin

Initiation and Initial Warfarin Dosing

Start warfarin on day 1 or 2 of unfractionated heparin (UFH) therapy using a reduced initial dose of 2–5 mg daily for patients who are ≥70 years old, weigh <70 kg, have chronic liver disease, or are taking interacting medications. 1
For patients ≥70 years and weight <70 kg, begin with 2–3 mg daily (approximately 1 mg less than the standard dose for younger adults). 2
In the presence of chronic liver disease, use a starting dose of <5 mg daily because hepatic impairment slows warfarin metabolism and reduces synthesis of vitamin K‑dependent clotting factors. 1
When amiodarone is co‑administered, reduce the warfarin dose by 30–50 % due to potent inhibition of warfarin metabolism. 1
With azole antifungals or macrolide antibiotics, anticipate a 25–40 % dose reduction and increase INR monitoring to every 1–2 days while the antibiotic is being taken. 1

Continue UFH infusion for at least 5 days and until the INR is ≥2.0 on two consecutive measurements taken >24 hours apart before stopping heparin. 3
The 5‑day minimum overlap is required because warfarin initially produces a paradoxical pro‑thrombotic state by depleting protein C (half‑life 6–8 h) before clotting factors II, IX, X (half‑lives 24–72 h). 3

Monitor INR daily until a stable therapeutic range (2.0–3.0) is achieved.
Once stable, check INR 2–3 times per week for 1–2 weeks, then weekly for 1 month, and monthly thereafter. 2
Patients ≥70 years should have more frequent INR checks because they exhibit greater INR variability during illness or medication changes. 2
During antibiotic therapy, obtain INR measurements every 1–2 days due to the high risk of rapid INR elevation. 4
In patients with liver disease, monitor INR every 2–3 days initially because hepatic dysfunction leads to unpredictable warfarin response. 1

If oral tablets cannot be taken, bridge with subcutaneous UFH 250 U/kg every 12 hours while initiating warfarin; warfarin tablets may be crushed or dissolved in water for administration via feeding tube. 1
Fixed‑dose subcutaneous UFH (≈250 U/kg q12 h, without routine laboratory monitoring) is safe and effective for VTE treatment and eliminates the need for continuous IV access. 1
Crushing warfarin tablets and mixing them with a small amount of food or liquid does not impair absorption. 2

High thrombotic risk (e.g., recent VTE, mechanical mitral valve, atrial fibrillation with prior stroke): maintain aggressive overlap with target aPTT 1.5–2.5 × control (anti‑Xa 0.3–0.7 IU/mL) throughout bridging and consider extending overlap beyond 5 days if INR remains sub‑therapeutic. 5
Low thrombotic risk (e.g., VTE >3 months ago, atrial fibrillation without prior stroke): the standard 5‑day overlap is sufficient. 5

Do not use a 10 mg loading dose of warfarin in elderly, low‑weight, or liver‑diseased patients; this frequently leads to supratherapeutic INR and bleeding. 2
Do not discontinue heparin when the INR first reaches 2.0; wait for two consecutive therapeutic INRs measured >24 hours apart. 4
Avoid subcutaneous low‑molecular‑weight heparin (LMWH) when creatinine clearance is <30 mL/min; use UFH instead to prevent drug accumulation. 1

All facts are derived from peer‑reviewed sources and reflect current evidence‑based recommendations.

Warfarin induces a transient pro‑thrombotic state during the first 3–5 days because protein C and protein S (half‑life 6–8 h) are depleted before clotting factors II, IX, and X (half‑lives 24–72 h) are sufficiently reduced; therefore concurrent heparin coverage is essential – American College of Cardiology [@5]
A minimum 5‑day overlap of heparin with warfarin is required even after the INR reaches 2.0, because an INR ≥ 2.0 reflects only depletion of factor VII and does not guarantee adequate reduction of factors II and X – American College of Chest Physicians [@1, @2, @3, @4]

Unfractionated heparin (IV): 80 units/kg bolus followed by 18 units/kg/h infusion, targeting an aPTT 1.5–2.5 × control – NCCN [@6, @7]
Unfractionated heparin (subcutaneous, fixed‑dose): 333 units/kg loading dose, then 250 units/kg every 12 h – NCCN [@6, @7]
Enoxaparin (LMWH): 1 mg/kg subcutaneously every 12 h – NCCN [@6, @7]
Dalteparin (LMWH): 200 units/kg subcutaneously once daily – NCCN [@6, @7]
Fondaparinux: weight‑based dosing (5 mg < 50 kg; 7.5 mg 50–100 kg; 10 mg > 100 kg) subcutaneously once daily – NCCN [@6, @7]

Start warfarin at 2.5–5 mg daily (avoid a 10 mg loading dose) for most patients – NCCN [@6, @7]
The American College of Chest Physicians permits a 10 mg daily dose for the first two days only in healthy out‑patients, with significant caveats – American College of Chest Physicians [@2, @3, @4]

Renal insufficiency (CrCl < 30 mL/min): use unfractionated heparin rather than LMWH because UFH is cleared hepatically; a fixed‑dose subcutaneous UFH regimen (250 units/kg q12 h) is safe in end‑stage renal disease without anti‑Xa monitoring – NCCN [@7]
Cancer patients:
- The NCCN recommends the same bridging approach—initiate warfarin concurrently with parenteral anticoagulation and continue both for ≥ 5 days until INR ≥ 2.0 for ≥ 24 h – NCCN [@6, @7]
- For cancer‑associated venous thromboembolism, direct oral anticoagulants or extended LMWH monotherapy are now preferred over warfarin – NCCN [@6, @7]

Starting warfarin on day 1–2 of heparin therapy shortens hospital length of stay by approximately 4 days without increasing mortality, recurrent thromboembolism, or major bleeding – American College of Chest Physicians [@1, @2, @3, @4]